請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/64697
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 曾宇鳳 | |
dc.contributor.author | Bo-Han Su | en |
dc.contributor.author | 蘇柏翰 | zh_TW |
dc.date.accessioned | 2021-06-16T22:57:36Z | - |
dc.date.available | 2017-08-28 | |
dc.date.copyright | 2012-08-28 | |
dc.date.issued | 2012 | |
dc.date.submitted | 2012-08-09 | |
dc.identifier.citation | 1. Brown, A. M., Drugs, hERG and sudden death. Cell. Physiol. Biochem. 2004, 35, 543-547.
2. Perlstein, R.; Vaz, R. J.; Rampe, D., Understanding the structure-activity relationship of the human ether-a-go-go-related gene cardiac K+ channel. A model for bad behaviour. J. Med. Chem. 2003, 46, 2017-2022. 3. Recanatini, M.; Poluzzi, E.; Masetti, M.; Cavalli, A.; De Ponti, F., QT prolongation through hERG K(+) channel blockade: Current knowledge and strategies for the early prediction during drug development. Med. Res. Rev. 2005, 25, 133-166. 4. Sanguinetti, M. C.; Jiang, C.; Curran, M. E.; Keating, M. T., A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encoded the Ikr potassium channel. Cell. Physiol. Biochem. 1995, 81, 299-307. 5. Doyle, D. A.; Morais Cabral, J.; Pfuetzner, R. A.; Kuo, A.; Gulbis, J. M.; Cohen, S. L.; Chait, B. T.; MacKinnon, R., The structure of the potassium channel: molecular basis of K+ conduction and selectivity. Science 1998, 280, 69-77. 6. Zhou, Y.; Morais-Carbral, J. H.; Kaufman, A.; MacKinnon, R., Chemistry of ion coordination and hydration revealed by a K+ channel-Fab complex at 2.0 A resolution. Nature 2001, 414, 43-8. 7. Jiang, Y.; Lee, A.; Chen, J.; Cadene, M.; Chait, B. T.; MacKinnon, R., Crystal structure and mechanism of a calcium-gated potassium channel. Nature 2002, 417, 515-22. 8. Jiang, Y.; Lee, A.; Chen, J.; Ruta, V.; Cadene, M.; Chait, B. T.; MacKinnon, R., X-ray structure of a voltage-dependent K+ channel. Nature 2003, 423, 33-41. 9. Long, S. B.; Campbell, E. B.; Mackinnon, R., Crystal structure of a mammalian voltage-dependent Shker family k+ channel. Science 2005, 309, 897-903. 10. Farid, R.; Day, T.; Friesner, R. A.; Pearlstein, R. A., New insights about HERG blockade obtained from protein modeling, potential energy mapping, and docking studies. Bioorg. Med. Chem. Lett. 2006, 14, 3160-73. 11. Osterberg, F.; Aqvist, J., Exploring blocker binding to a homology model of the open hERG K+ channel using docking and molecular dynamics methods. FEBS Lett. 2005, 579, 2939-44. 12. Rajamani, R.; Tounge, B. A.; Li, J.; Reynolds, C. H., A two-state homology model of the hERG K+ channel: application to ligand binding. Bioorg. Med. Chem. Lett. 2005, 15, 1737-41. 13. Senese, C. L.; Duca, J.; Pan, D.; Hopfinger, A. J.; Tseng, Y. J., 4D-Fingerprints, Universal QSAR and QSPR Descriptors. J. Chem. Inf. Comput. Sci. 2004, 44, (5), 1526-1539. 14. MOE (Molecular Operating Environment), 2008.10; Chemical Computing Group, Inc.: Montreal, Canada, 2008. 15. Cruciani, G.; Pastor, M.; Guba, W., VolSurf: a new tool for the pharmacokonetic optimization of lead compounds. Eur. J. Pharm. Sci. 2000, 11, S29-S39. 16. Talete, S. R. L. DRAGON for Windows (software for molecular descriptor calculations), Version 5.4; 2006. 17. Stuper, A. J.; Jurs, P. C., ADAPT: A Computer System for Automated Data Analysis Using Pattern Recognition Techniques. J. Chem. Inf. Comput. Sci. 1976, 16, (2), 99-105. 18. MOLCONN-Z. http://www.eslc.vabiotech.com/molconn/ 19. Song, M.; Clark, M., Development and evaluation of an in silico model for hERG binding. J. Chem. Inf. Model 2006, 46, 392-400. 20. Yoshida, K.; Niwa, T., Quantitative structure-activity relationship studies on inhibition of HERG potassium channels. J. Chem. Inf. Model 2006, 46, 1371-8. 21. Seierstad, M.; Agrafiotis, D. K., A QSAR model of HERG binding using a large, diverse, and internally consistent training set. chem. Biol. Drug. Des. 2006, 67, 284-96. 22. Gavaghan, C. L.; Arnby, C. H.; Blomberg, N.; Strandlund, G.; Boyer, S. J., Development, interpretation and temporal evaluation of a global QSAR of hERG electrophysiology screening data. J. Comput.-Aided Mol. Des. 2007, 21, 189-206. 23. Hall, L. H.; Kier, L. B., Reviews in Computational Chemistry. 1991; Vol. 2. 24. Ghose, A. K.; Viswanadhan, V. N.; Wendoloski, J. J., Prediction of hydrophobic (lipophilic) properties of small organic molecules using fragmental methods: an analysis of ALOGP and CLOGP methods. J. Phys. Chem. A 1998, 102, 3762-3772. 25. Bruneau, P., Search for Predictive Generic Model of Aqueous Solubility Using Bayesian Neural Nets. J. Chem. Inf. Comput. Sci. 2001, 41, (6), 1605-1616. 26. Bridgland-Taylora, M. H.; Hargreavesb, A. C.; Eastera, A.; Ormeb, A.; Henthornb, D. C.; Dingc, M.; Davisd, A. M.; Smalla, B. G.; Heapya, C. G.; Abi-Gergesa, N.; Perssone, F.; Jacobsone, I.; Sullivanb, M.; Albertsonc, N.; Hammonda, T. G.; Sullivanb, E.; Valentina, J.-P.; Pollard, C. E., Optimisation and validation of a medium-throughput electrophysiology-based hERG assay using IonWorks™ HT. J. Pharmacol. Toxicol. Methods 2006, 54, (2), 189-99. 27. Ekins, S.; Crumb, W. J.; Sarazan, R. D.; Wikel, J. H.; Wrighton, S. A., Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel. J. Pharmacol. Exp. Ther. 2002, 301, 427-34. 28. Cavalli, A.; Poluzzi, E.; De Ponti, F.; Recanatini, M., Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers. J. Med. Chem. 2002, 45, 3844-53. 29. Pearlstein, R. A.; Vaz, R. J.; kang, J.; Chen, X. L.; Preobrazhenskaya, M.; Shchekotikhin, A. E.; Korolev, A. M.; Lysenkova, L. N.; Miroshnikova, O. V.; Hendrix, J.; Rampe, D., Characterization of hERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches. Bioorg. Med. Chem. Lett. 2003, 13, 1829-1835. 30. Li, Q.; Jorgensen, F. S.; Oprea, T.; Brunak, S.; Taboureau, O., hERG Classification Model Based on a Combination of Support Vector Machine Method and GRIND Descriptors. Mol. Pharmaceutics 2008, 5, (2), 117-127. 31. Chekmarev, D. S.; Kholodovych, V.; Balakin, K. V.; Ivanenkov, Y.; Ekins, S.; Welsh, W. J., Shape signatures: new descriptors for predicting cardiotoxicity in silico. Chem. Res. Toxicol. 2008, 21, (6), 1304-1314. 32. Pastor, M.; Cruciani, G.; McLay, I.; Pickett, S.; Clementi, S., GRid-INdependent descriptors (GRIND): a novel class of alignment-independent three-dimensional molecular descriptors. J. Med. Chem. 2000, 43, (17), 3233-3243. 33. Thai, K. M.; Ecker, G. F., A binary QSAR model for classification of hERG potassium channel blockers. BIoorg. Med. Chem. 2008, 16, (7), 4107-19. 34. Sun, H., An accurate and interpretable bayesian classification model for prediction of HERG liability. ChemMedChem 2006, 1, (3), 315-322. 35. Su, B.-H.; Shen, M.-y.; Esposito, E. X.; Hopfinger, A. J.; Tseng, Y. J., In Silico Binary Classification QSAR Models Based on 4D-Fingerprints and MOE Descriptors for Prediction of hERG Blockage. J. Chem. Inf. Model. 2010, 50, (7), 1304–1318. 36. Rogers, D.; Hopfinger, A. J., Application of genetic function approximation to quantitative structure-activity relationships and quantitative structure-property relationships. J. Chem. Inf. Comput. Sci. 1994, 34, 854-866. 37. Bains, W.; Basman, A.; White, C., hERG binding specificity and binding site structure: evidence from a fragment-based evolutionary computing SAR study. Prog. Biophys.Mol. Bio. 2004, 86, 205-233. 38. Dubus, E.; Ijjaali, I.; Petitet, F.; Michel, A., In silico classification of hERG channel blockers: a knowledge-based strategy. ChemMedChem 2006, 1, (6), 622-630. 39. Keseru, G. M., Prediction of hERG potassium channel affinity by traditional and hologram QSAR methods. Bioorg. Med. Chem. Lett. 2003, 13, 2773-2775. 40. Nisius, B.; Goller, A. H., Similarity-Based Classifier Using Topomers to Provide a Knowledge Based for hERG Channel Inhibition. J. Chem. Inf. Model. 2008, 49, 247-256. 41. Roche, O.; Trube, G.; Zuegge, J.; Pflimlin, P.; Alanine, A.; Schneider, G., A virtual screening method for prediction of the hERG potassium channel liability of compound libraries. ChemBioChem 2002, 3, 455-459. 42. Shen, M.-y.; Su, B.-H.; Esposito, E. X.; Hopfinger, A. J.; Tseng, Y. J., A comprehensive support vector machine binary hERG classification model based on extensive but biased end point hERG data sets. Chem. Res. Toxicol. 2011, 24, (6), 934-949. 43. Huang, J.; Fan, X., Why QSAR fails: an empirical evaluation using conventional computational approach. Mol. Pharmaceutics 2011, 8, (2), 600-608. 44. Taglialatela, M.; Pannaccione, A.; Castaldo, P.; Giorgio, G.; Zhou, Z.; January, C.; Genovese, A.; Marone, G.; Annunziato, L., Molecular Basis for the Lack of HERG K+ Channel Block-Related Cardiotoxicity by the H1 Receptor Blocker Cetirizine Compared with Other Second-Generation Antihistamines. Mol. Pharmacol. 1998, 54, 113-121. 45. Zerhouni, E., The NIH Roadmap. SCIENCE 2003, 302, 63-72. 46. Wang, Y.; Xiao, J.; Suzek, T. O.; Zhang, J.; Wang, J.; Bryant, S. H., PubChem: a public information system for analyzing bioactivities of small molecules. Nucl. Acids Res. 2009, 37, W623-33. 47. Japkowicz, N.; Stephen, S., The class imbalance problem: A systematic study. Intelligent Data Analysis 2002, 6, (5), 429-449. 48. Chawla, N.; Japkowicz, N.; olcz, A., Editorial: special issue on learning from imbalanced data sets. SIGKDD Explorations 2004, 6, (1), 1-6. 49. Akbani, R.; Kwek, S.; Japkowicz, N. In Applying support vector machines to imbalanced datasets, Machine Learning: ECML 2004, pp 39-50. 50. Wu, G.; Chang, E. Y., KBA: Kernel Boundary Alignment Considering Imbalanced Data Distribution. IEEE Transactions on Knowledge and Data Engineering 2005, 17, (6), 786-795. 51. Raskutti, B.; Kowalczyk, A., Extreme re-balancing for SVMs: a case study. SIGKDD Explorations 2004, 6, (1), 60-69. 52. Guha, R.; Schurer, S. C., Utilizing high throughput screening data for predictive toxicology models: protocols and application to MLSCN assays. J. Comput. Aided Mol. Des. 2008, 22, 367-384. 53. Li, Q.; Wang, Y.; Bryant, S. H., A novel method for mining highly imbalanced high-throughput screening data in PubChem. Bioinformatics 2009, 25, (24), 3310-3316. 54. Vapnik, V. N., Statistical Learning Theory. Wiley: New York, 1998; p 736 %@ 0471030031 %L pc17 to sa00 08-22-97; je07 08-27-97 sent to subj.; 27Aug97 JE08 to SL; je05 to DDC 08-29-97; CIP ver. jp99 11-06-98. 55. Vapnik, V. N., The nature of statistical learning theory. 2000. 56. Yuchun Tang, Y.-Q. Z., Nitesh V. Chawla, and Sven Krasser, SVMs Modeling for Highly Imbalanced Classification. IEEE Transactions on System, Man, and Cybernetics - Part B: Cybernetics 2009, 39, (1), 281-288. 57. American Chemical Society, SciFinder Scolar. Version 2007. In 2007 ed.; Chemical Abstracts Service, Columbus, Ohio, USA, 2007. 58. Hypercube Hyperchem Release 7.0, 2008. 59. Allinger, N. L., Conformational analysis. 130. MM2. A hydrocarbon force field utilizing V1 and V2 torsional terms. J. Am. Chem. Soc. 1977, 99, (25), 8127-8134. 60. Weller, H. N., Purification of combinatorial libraries. Molecular Diversity 1999, 4, 47-52. 61. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J., Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Del. Rev. 1997, 23, 3-25. 62. Holland, J. H., Adaptation in Natural and Artificial Systems. University of Michigan Press: Ann Arbor, 1975. 63. Friedman, J. Multivariate AdaptiveRegression Splines, Technical Report No. 102; Laboratory for Computational Statistics, Department of Statistics, Stanford University; Stanford, CA, Nov 1988 (revised Aug 1990). 64. Fan, R.-E.; Chen, P.-H.; Lin, C.-J., Working set selection using the second order information for training SVM. J. M. L. R. 2005, 6, 1889-1918. 65. Cohen, J., A Coefficient of Agreement for Nominal Scales. Educational and Psychological Measurement 1960, 20, (1), 37-46. 66. Aronov, A. M.; Goldman, B. B., A model for identifying HERG K+ channel blockers. BIoorg. Med. Chem. 2004, 12, 2307-2315. 67. O'Brien, S. E.; de Groot, M. J., Greater than the sum of its parts: combining models for useful ADMET prediction. J. Med. Chem. 2005, 48, 1287-1291. 68. Fioravanzo, E.; Cazzolla, N.; Durando, L.; Ferrari, C.; Mabilia, M.; Ombrato, R.; Parenti, M. D., General and Independent Approaches to Predict HERG Affinity Values. Internet Electronic J. Mol. Des. 2005, 4, 625-646. 69. Tobita, M.; Nishikawa, T.; Nagashima, R., A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors. Bioorg. Med. Chem. Lett. 2005, 15, 2886-2890. 70. Roche, O.; Trube, G.; Zuegge, J.; Pflimlin, P.; Alanine, A.; Schneider, G., A virtual screening method for prediction of the HERG potassium channel liability of compound libraries. Chembiochem 2002, 3, 455-9. 71. Gasteiger, J.; Marsili, M., Iterative partial equalization of orbital electronegative - a rapid access to atomic charges. Tetrahedron 1980, 36, 3219-3288. 72. Aha, D., Tolerating noisy, irrelevant and novel attributes in instance-based learning algorithms. Int. J. Man-Mach. Studies 1992, 36, (2), 267-287. 73. Keseru, G. M., Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods. Bioorg. Med. Chem. Lett. 2003, 13, 2773-5. 74. Bains, W.; Basman, A.; White, C., HERG binding specificity and binding site structure: evidence from a fragment-based evolutionary computing SAR study. Prog. Biophys. Mol. Biol. 2004, 86, 205-33. 75. Duca, J. S.; Hopfinger, A. J., Estimation of Molecular Similarity Based on 4D-QSAR Analysis: Formalism and Validation. J. Chem. Inf. Comput. Sci. 2001, 41, 1367-1387. 76. Wildman, S. A.; Crippen, G. M., Prediction of Physiochemical Parameters by Atomic Contributions. J. Chem. Inf. Comput. Sci. 1999, 39, (5), 868-873. 77. Gasteiger, J.; Marsili, M., Iterative Partial Equalization of Orbital Electronegativity - A Rapid Access to Atomic Charges. Tetrahedron 36 1980, 3219. 78. PubChem. http://pubchem.ncbi.nlm.nih.gov/assay/assay.cgi?cid=376 (November 18, 2008), 79. Sun, H., A Universal Molecular Descriptor System for Prediction of LogP, LogS, LogBB, and Absorption. J. Chem. Inf. Comput. Sci. 2004, 44, 748-757. 80. Linden, A., Measuring diagnostic and predictive accuracy in disease management: an introduction to receiver operating characteristic (ROC) analysis. J. Eval. Clin. Pract. 2006, 12, (2), 132– 9. 81. Jia, L.; Sun, H., Support vector machines classification of hERG liabilities based on atom types. Bioorg. Med. Chem. 2008, 16, (11), 6252-6260. 82. Akay, M. F., Support vector machines combined with feature selection for breast cancer diagnosis. Expert Syst. Appl. 2009, 36, 3240-3247. 83. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J., Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings. Adv. Drug Deliver. Rev. 1997, 23, 3-25. 84. Song, M.; Clark, M., Development and evaluation of an in silico model for hERG binding. J. Chem. Inf. Model. 2006, 46, 392-400. 85. Tseng, Y.; Hopfinger, A.; Esposito, E., The Great Descriptor Melting Pot: Mixing Descriptors for the Common Good of QSAR Models. Journal of Computer-Aided Molecular Design 2012, 26, (1), 39-43. 86. Bajorath, J., Integration of virtual and high-throughput screening. Nat. Rev. Drug Discov. 2002, 1, 882–894. 87. Lengauer, T.; Lemmen, C.; Rarey, M.; Zimmermann, M., Zimmermann, Novel technologies for virtual screening. Drug Discov. Today 2004, 9, 27–34. 88. Xu, H.; Agrafiotis, D. K., Retrospect and prospect of virtual screening in drug discovery. Curr. Top. Med. Chem. 2002, 2, 1305–1320. 89. Alvarez, J. C., High-throughput docking as a source of novel drug leads. Curr. Opin. Chem. Biol. 2004, 8, (4), 365-370. 90. Schneider, G.; Fechner, U., Computer-based de novo design of drug-like molecules. Nat. Rev. Drug. Discovery 2005, 4, 649-663. 91. Dey, F.; Caflisch, A., Fragment-Based de Novo Ligand Design by Multiobjective Evolutionary Optimization. Journal of Chemical Information and Modeling 2008, 48, (3), 679-690. 92. Schneider, G.; Lee, M. L.; Stahl, M.; Schneider, P., De novo design of molecular architectures by evolutionary assembly of drug-derived building blocks. J. Comput.-Aided Mol. Des. 2000, 14, 487-494. 93. Pegg, S. C.; Haresco, J. J.; Kuntz, I. D., A genetic algorithm for structure-based de novo design. J. Comput.-Aided Mol. Des. 2001, 15, (10), 911-33. 94. Liu, Q.; Masek, B.; Smith, K.; Smith, J., Tagged Fragment Method for Evolutionary Structure-Based De Novo Lead Generation and Optimization. J. Med. Chem. 2007, 50, (22), 5392–5402. 95. Wang, R.; Gao, Y.; Lai, L., LigBuilder: A Multi-Purpose Program for Structure-Based Drug Design. J. Mol. Model. 2000, 6, (7-8), 498-516. 96. Gillet, V.; Johnson, A. P.; Mata, P.; Sike, S.; Williams, P., SPROUT: A program for structure generation. J. Comput.-Aided Mol. Des. 1993, 7, (2), 127-153. 97. Bohacek, R. S.; McMartin, C., Multiple Highly Diverse Structures Complementary to Enzyme Binding Sites: Results of Extensive Application of a de Novo Design Method Incorporating Combinatorial Growth. J. Am. Chem. Soc. 1994, 116, (13), 5560–5571. 98. Pearlman, D. A.; Murcko, M. A., CONCERTS: Dynamic Connection of Fragments as an Approach to de Novo Ligand Design. J. Med. Chem. 1996, 39, (8), 1651–1663. 99. Metropolis, N.; Rosenbluth, A. W.; Rosenbluth, M. N.; Teller, A. H.; Teller, E., Equation of State Calculations by Fast Computing Machines. J. Chem. Phys. 1953, 21, 1087-1092. 100. Vinkers, H. M.; de Jonge, M. R.; Daeyaert, F. F.; Heeres, J.; Koymans, L. M.; van Lenthe, J. H.; Lewi, P. J.; Timmerman, H.; Van Aken, K.; Janssen, P. A., SYNOPSIS: SYNthesize and OPtimize System in Silico. J Med Chem. 2003, 46, (13), 2765-73. 101. Lewell, X. Q.; Judd, D. B.; Watson, S. P.; Hann, M. M., RECAP-Retrosynthetic Combinatorial Analysis Procedure: A Powerful New Technique for Identifying Privileged Molecular Fragments with Useful Applications in Combinatorial Chemistry. J. Chem. Inf. Comput. Sci. 1998, 38, (3), 511–522. 102. Cramer, R. D.; Soltanshahi, F.; Jilek, R.; Campbell, B., AllChem: generating and searching 1020 synthetically accessible structures. J. Comput. Aided Mol. Des. 2007, 21, (6), 341-350. 103. Hecht, D.; Fogel, G. B., A Novel In Silico Approach to Drug Discovery via Computational Intelligence. J. Chem. Inf. Model. 2009, 49, (4), 1105–1121. 104. Douguet, D.; Munier-Lehmann, H.; Labesse, G.; Pochet, S., LEA3D: A Computer-Aided Ligand Design for Structure-Based Drug Design. J. Med. Chem. 2005, 48, 2457– 2468. 105. Burns, J. A.; Whitesides, G. M., Feed-Forward Neural Networks in Chemistry: Mathematical Systems for Classification and Pattern Recognition. Chem. Rev. 1993, 93, 2583-2601. 106. Kosko, B.; Isaka, S., Fuzzy Logic. Sci. Am. 1993, 62-67. 107. Verdonk, M. L.; Rees, D. C., Group efficiency: a guideline for hits-to-leads chemistry. ChemMedChem. 2008, 3, (8), 1179-80. 108. I. D. Kuntz, K. C., K. A. Sharp and P. A. Kollman, The maximal affinity of ligands. PNAS 1999, 96, 9997-10002. 109. Hopkins, A. L.; Groom, C. R.; Alex, A., Ligand efficiency: a useful metric for lead selection. Drug Discov. Today 2004, 9, (10), 430-431. 110. Teague, S. J.; Davis, A. M.; Leeson, P. D.; Oprea, T., The Design of Leadlike Combinatorial Libraries. Angew. Chem. Int. Ed. 1999, 38, (24), 3743-3748. 111. Navia, M. A.; Chaturvedi, P. R., Design principles for orally bioavailable drugs. Drug Discov. Today 1996, 1, (5), 179-189. 112. Lipinski, C. A., Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 2000, 44, (1), 235-249. 113. Saxty, G.; Woodhead, S. J.; Berdini, V.; Davies, T. G.; Verdonk, M. L.; Wyatt, P. G.; Boyle, R. G.; Barford, D.; Downham, R.; Garrett, M. D.; Carr, R. A., Identification of Inhibitors of Protein Kinase B Using Fragment-Based Lead Discovery†. Journal of Medicinal Chemistry 2007, 50, (10), 2293-2296. 114. Reynolds, C. H.; Tounge, B. A.; Bembenek, S. D., Ligand Binding Efficiency: Trends, Physical Basis, and Implications. Journal of Medicinal Chemistry 2008, 51, (8), 2432-2438. 115. Perola, E., An Analysis of the Binding Efficiencies of Drugs and Their Leads in Successful Drug Discovery Programs. Journal of Medicinal Chemistry 2010, 53, (7), 2986-2997. 116. Reynolds, C. H.; Bembenek, S. D.; Tounge, B. A., The role of molecular size in ligand efficiency. Bioorg. Med. Chem. Lett. 2007, 17, 4258-4261. 117. Liu, Y.; Gray, N. S., Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol 2006, 2, (7), 358-364. 118. Karaman, M. W.; Herrgard, S.; Treiber, D. K.; Gallant, P.; Atteridge, C. E.; Campbell, B. T.; Chan, K. W.; Ciceri, P.; Davis, M. I.; Edeen, P. T.; Faraoni, R.; Floyd, M.; Hunt, J. P.; Lockhart, D. J.; Milanov, Z. V.; Morrison, M. J.; Pallares, G.; Patel, H. K.; Pritchard, S.; Wodicka, L. M.; Zarrinkar, P. P., A quantitative analysis of kinase inhibitor selectivity. Nat Biotech 2008, 26, (1), 127-132. 119. Clark, J. W.; Eder, J. P.; Ryan, D.; Lathia, C.; Lenz, H. J., Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin. Cancer Res. 2005, 11, (15), 5472-5480. 120. Weisberg, E.; Manley, P. W.; Breitenstein, W.; Bruggen, J.; Cowan-Jacob, S. W.; Ray, A.; Huntly, B.; Fabbro, D.; Fendrich, G.; Hall-Meyers, E.; Kung, A. L.; Mestan, J.; Daley, G. Q.; Callahan, L.; Catley, L.; Cavazza, C.; Azam, M.; Neuberg, D.; Wright, R. D.; Gilliland, D. G.; Giffin, J. D., Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005, 7, (129-141). 121. Smith, A. L.; DeMorin, F. F.; Paras, N. A.; Huang, Q.; Petkus, J. K.; Doherty, E. M.; Nixey, T.; Kim, J. L.; Whittington, D. A.; Epstein, L. F.; Lee, M. R.; Rose, M. J.; Babij, C.; Fernando, M.; Hess, K.; Le, Q.; Beltran, P.; Carnahan, J., Selective Inhibitors of the Mutant B-Raf Pathway: Discovery of a Potent and Orally Bioavailable Aminoisoquinoline. J. Med. Chem. 2009, 52, (20), 6189–6192. 122. Scott M. Wilhelm, C. C., LiYa Tang, Dean Wilkie, Angela McNabola, Hong Rong, Charles Chen, Xiaomei Zhang, Patrick Vincent, Mark McHugh, Yichen Cao, Jaleel Shujath, Susan Gawlak, Deepa Eveleigh, Bruce Rowley, Li Liu, Lila Adnane, Mark Lynch, Daniel Auclair, Ian Taylor, Rich Gedrich, Andrei Voznesensky, Bernd Riedl, Leonard E. Post, Gideon Bollag, and Pamela A. Trail, BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis Cancer Research 2004, 64, 7099-7109. 123. Hatzivassiliou, G.; Song, K.; Yen, I.; Brandhuber, B. J.; Anderson, D. J.; Alvarado, R.; Ludlam, M. J. C.; Stokoe, D.; Gloor, S. L.; Vigers, G.; Morales, T.; Aliagas, I.; Liu, B.; Sideris, S.; Hoeflich, K. P.; Jaiswal, B. S.; Seshagiri, S.; Koeppen, H.; Belvin, M.; Friedman, L. S.; Malek, S., RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010, 464, (7287), 431-435. 124. Alavi, A.; Hood, J. D.; Frausto, R.; Stupack, D. G.; Cheresh, D. A., Role of Raf in vascular protection from distinct apoptotic stimuli. Science 2003, 301, 94–96. 125. Wan, P. T.; Garnett, M. J.; Roe, S. M.; Lee, S.; Niculescu-Duvaz, D.; Good, V. M.; Jones, C. M.; Marshall, C. J.; Springer, C. J.; Barford, D.; Marais, R., Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004, 116, 855-867. 126. Golemovic, M.; Verstovsek, S.; Giles, F.; Cortes, J.; Manshouri, T.; Manley, P. W.; Mestan, J.; Dugan, M.; Alland, L.; Griffin, J. D.; Arlinghaus, R. B.; Sun, T.; Kantarjian, H.; Beran, M., AMN107, a novel aminopyrimidine inhibitor of BCR-ABL, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin. Cancer Res. 2005, 11, 4941–4947. 127. Bartram, C. R.; de Klein, A.; Hagemeijer, A.; van, A. T.; Geurts, v. K. A.; Bootsma, D.; Grosveld, G.; Ferguson-Smith, M. A.; Davies, T.; Stone, M.; Heisterkamp, N.; Stephenson, J. R.; Groffen, J., Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1983, 306, 277–280. 128. Chan, L. C.; Karhi, K. K.; Rayter, S. I.; Heisterkamp, N.; Eridani, S.; Powle, R.; Lawler, S. D.; Groffen, J.; Foulkes, J. G.; Greaves, M. F.; Wiedemann, L. M., A novel abl protein expressed in Philadelphia chromosome positive acute lymphoblastic leukaemia. Nature 1987, 325, 635–637. 129. Groffen, J.; Stephenson, J. R.; Heisterkamp, N.; de Klein, A.; Bartram, C.; Grosveld, G., Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 1984, 36, 93–99. 130. Lugo, T. G.; Pendergast, A. M.; Muller, A. J.; Witte, O. N., Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990, 247, 1079–1082. 131. Morphy, R., Selectively Nonselective Kinase Inhibition: Striking the Right Balance. Journal of Medicinal Chemistry 2009, 53, (4), 1413-1437. 132. Kantarjian, H. M.; F., G.; Gattermann, N.; Bhalla, K.; Alimena, G.; Palandri, F.; Ossenkoppele, G. J.; Nicolini, F.-.; O'Brien, S. G.; Litzow, M.; Bhatia, R.; Cervantes, F.; Haque, A.; Shou, Y.; Resta, D. J.; Weitzman, A.; Hochhaus, A.; Coutre, P. l., Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007, 110, (10), 3540-3546. 133. Sekulic, A.; Haluska, P. J.; Miller, A. J.; Genebriera De Lamo, J.; Ejadi, S.; Pulido, J. S.; D.R., S.; E.C., T.; R.G., V.; D.L., S.; B.A., P.; S.D., L.; M.R., P.; Markovic, S. N., Malignant Melanoma in the 21st Century: The Emerging Molecular Landscape. Mayo Clin. Pro. 2008, 83, (7), 825-846. 134. Sigma-Alderich Chemie GmbH,Steinheim, Germany. In. 135. Molinspiration. http://www.molinspiration.com/docu/fragments/index.html 136. Trott, O.; Olson, A. J., AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of Computational Chemistry 2010, 31, (2), 455-461. 137. Fragment-Based Drug Design: How Big Is Too Big? Journal of Medicinal Chemistry 2006, 49, (24), 6972-6976. 138. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J., Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews 1997, 23, (1-3), 3-25. 139. HyperChem(TM) Professional 7.51, H., Inc., 1115 NW 4th Street, Gainesville, Florida 32601, USA 140. Polak, E., Computational Methods in Optimization. Academic Press: New York, 1971. 141. Erik Lindahl, B. H. a. D. v. d. S., GROMACS 3.0: A package for molecular simulation and trajectory analysis J. Mol. Mod. 2001, 7, 306-317. 142. Berendsen, H. J. C.; Postma, J. P. M.; van Gunsteren, W. F.; Hermans, J., Interaction Models for Water in Relation to Protein Hydration. D. Reidel Publishing Company: Dordrecht, The Netherlands, 1981. 143. Berendsen, H. J. C.; Postma, J. P. M.; Di Nola, A.; van Gunsteren, W. F.; Haak, J. R., Molecular dynamics with coupling to an external bath. J. Chem. Phys. 1984, 81, (8), 3684-3690. 144. Zhang, C.; Qi, M.; Shao, Q.; Zhou, S.; Fu, R., Analysis of the volatile compounds in Ligusticum chuanxiong Hort. using HS-SPME-GC-MS. Journal of Pharmaceutical and Biomedical Analysis 2007, 44, (2), 464-470. 145. Harn, Y. C.; Tseng, Y. J., Structure Hunter: Prediction of novel chemical structures in a mixture. In 7th International Conference of the Metabolomics Society, Cairns, Australia, 2011. 146. Ibarra, O. H.; Kim, C. E., Fast approximation algorithms for the knapsack and sum of subset problems. Journal of ACM 1975, 22, 463-468. 147. Martello, S.; Toth, P., Knapsack Problems. J. Wilev & Sons: Chichester, 1990. 148. Garey, M. R.; Johnson, D. S., Computers and Intractability; A Guide to the Theory of NP-Completeness. New York, NY, USA 1990. 149. Karp, R. M., Reducibility among combinatorial problems In Complexity of Computer Computations. Plenum: New York, 1972. 150. Garey, M. R.; Johson, D. S., Strong ' NP-Completeness Results: Motivation, Examples, and Implications. J. ACM 1978, 25, 499-508. 151. Horowitz, E.; Sahni, S., Fundamentals of Computer Algorithms. Computer Science Press: 1978. 152. Dictionary of Natural Products. 2005. 153. Irwin, J. J.; Shoichet, B. K., ZINC − A free database of commercially available compounds for virtual screening. Journal of Chemical Information and Modeling 2004, 45, (1), 177-182. 154. Chen, C. Y.-C., TCM Database@Taiwan: The World's Largest Traditional Chinese Medicine Database for Drug Screening In Silico. PLoS ONE 2011, 6, (1), e15939. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/64697 | - |
dc.description.abstract | 為了有效加速傳統藥物設計的發展時程,本篇論文分別針對電腦輔助藥物設計中最重要的先導化合物的辨識階段、結構最佳化階段與吸收、分配、代謝、排泄和毒性(ADMET)之測試階段各提出了一項研究主題。
在ADMET的測試階段,我們針對人類鉀離子通道基因(hERG)毒性試驗資料發展一系列的電腦分類模型,以進行毒理(T)之預測。為了針對三種難以處理又具不同型態的hERG毒性資料進行預測,我們使用了二元定量構效關係(QSAR)模型與支援向量機(SVM)兩種策略來進行系統之建置。三種訓練集合資料包括:從文獻上搜集來的傳統劑量反應活性資料集合、具有”活性-非活性”之資料分佈高度不均的高通量篩選(high-throughput screening)數據集合、以及文獻上難以處理的hERG試驗資料集合。針對傳統劑量反應活性資料集合,我們以連續性部分最小平方(partial least squares)QSAR模型為基底轉換成二元QSAR模型之策略來增加預測hERG毒性之準確性。在第二個hERG的研究中,除了利用SVM來進行系統建置外,提出了各種合理的策略來有效降低在訓練集合中,活性與非活性資料之間分佈高度不均的情形。在最後一項hERG的研究中,特別以一組難以處理的資料集合為範例,提出一套可用來建立良好的QSAR預測模型之標準程序。因為在前人研究中皆難以利用此資料來建立較佳的預測模組,為了展示如何針對此集合來建構出一套良好的QSAR預測模型,我們延用前兩項提出的方法來進行發展與討論。以上三個所建構的QSAR模組之預測準確性皆比起過去曾發表的系統還高出許多。此外,系統所辨識出的重要特徵可以直接描繪在三維分子結構上,作為是否會增加或減少hERG毒性之依據。在藥物研發的過程中,我們所發展的系統可以提供化學結構上該如何修飾之資訊,以避免合成出具有心臟毒性的藥物。 在結構最佳化階段,我們針對第二型激化酵素抑制劑(Type II kinase inhibitors),發展了一套新的以模板為基底的新藥設計方法。將已知具有潛力的抑制劑作為模版來設計出可保有原結合交互作用力之新抑制劑。首先,以兩個已上市之藥物(Sorafenib與Nilotinib)作為模版,發展出共有五個步驟的協定可以從大量的片段結構資料庫重組出每一種藥物。在我們的系統測試下,所選擇的兩種上市藥物可經由我們的演算法成功地被重組出來。此外,為了能顯示本系統能夠找出更具潛力的結構,我們從一系列的氨基異喹啉(aminoisoquinoline)衍生物中挑出一個具有較低活性的化合物作為模版,以辨識出此系列衍生物中其它具較有高活性的結構。 在先導化合物的辨識階段,為了解決一個非完全多項式(NP complete)我們稱之為化學結構組合的最佳化問題,可有效針對天然產物進行結構辦識。我們設計出一個動態規劃(dynamic programming)演算法,並以迭代動態規劃演算法進行加速,其時間複雜度在平均情況下可在多項式時間內完成。為了驗證演算法在真實情況下的系統效能和確認是否能有效地找出最佳結構,套用了四種不同的天然物作為測試。本演算法的實際執行時間遠小於暴力演算法與前人以分支界定(branch and bound)所發表之演算法。此外,相較於前人所設計的分支界定演算法可能會有無法找到最佳解的情況,本演算法針對這四種測試資料,皆可在合理的時間內找到最佳解。 | zh_TW |
dc.description.abstract | To speed up the development of traditional drug design process, three works for lead discovery, lead optimization, and absorption, distribution, metabolism, excretion, and toxicity (ADMET) stage that computer-aided drug discovery can help in a drug discovery and development process were presented in this thesis.
In the stage of ADMET, predictive toxicology (T) modeling was performed to develop in silico classification models on hERG toxicity endpoints. Both binary QSAR and SVM strategies against three different typical and yet difficult hERG toxicity were performed. Three training datasets are composed of a traditional dose response study collected from literatures, a high-throughput screening assay with highly imbalanced active-inactive data distribution, and notoriously difficult hERG endpoints dataset claimed to be impossoble to model by other researchers. A binary QSAR model transformed from the continuous partial least squares (PLS) QSAR model to enhance the predictive reliability of hERG blockage was developed for traditional dose response studies. In second hERG study, SVM and training set compounds pruning from the proposed protocol to address the typical imbalanced active-versus-inactive data in high throughput screening assay were discussed and performed. In the last part of hERG studies, to demonstrate how to establish a good QSAR model for large datasets that are chemically diverse and highly imbalanced dataset (notoriously difficult endpoints), the previous two strategies were performed to construct, analyze, and discuss QSAR models for the third hERG dataset. The accuracies of three QSAR models discussed herein are all markedly better than other published classification models. In addition, the key descriptors that can be portrayed as 3D molecular features contributing to both increasing and decreasing hERG potency were identified and discussed. The models can benefit chemical structures designs in drug discovery process to avoid synthesizing cardio toxic compounds originated from hERG channel protein. In lead optimization, a novel template-based de novo design algorithm and protocol for type II kinase inhibitors was reported. Well-known potent inhibitors were used as a template to discover new inhibitors that preserve the binding interaction. First, Sorafenib (NexavarR) and Nilotinib (TasignaR) were selected as the template compounds. The proposed five-step protocol can reassemble each drug from a large fragment library. Our procedure demonstrates that the selected template compounds can be successfully reassembled while the key ligand-receptor interactions are preserved. Furthermore, to demonstrate that the algorithm is able to construct more potent compounds, the de novo optimization was initiated using a template compound possessing a less than optimal activity from a series of aminoisoquinoline derivatives. In lead discovery, to effectively identify the chemical structures of natural products, we studied a NP-complete problem, Chemical Substituents-Core Combinatorial Problem. We developed a classical dynamic programming algorithm and designed another iterative dynamic programming algorithm to improve time performance that can be executed in polynomial time in average case. Four natural products cases that were experimentally measured and structurally determined are applied in this study to verify the time performance of this algorithm. The execution time of this algorithm outperforms the previous published branch and bound strategy and brute force algorithm. Furthermore, it can be used to search for the real optimal solutions in an acceptable time for the four cases compared to the lengthy and un-determined search in the previous branch bound strategy. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T22:57:36Z (GMT). No. of bitstreams: 1 ntu-101-D95922021-1.pdf: 3180347 bytes, checksum: 1b9276aacb437df18afd506c97f9523d (MD5) Previous issue date: 2012 | en |
dc.description.tableofcontents | 口試委員會審定書 i
誌謝 ii 中文摘要 iv Abstract vi Contents viii List of Figures xii List of Tables xvii 1 In Silico hERG Toxicity Prediction 1 1.1 Introduction 1 1.1.1 Background 1 1.1.2 A Binary QSAR Models to a High-Quality Assay Data Set 6 1.1.3 A SVM Classification Model to a High-Throughput Screening Data with Imbalanced Data Distribution 7 1.1.4 Recipes for Notoriously Difficult Endpoints – an hERG Toxicity Dataset 11 1.2 Materials and Methods 12 1.2.1 Materials 12 1.2.1.1 High-Quality Assay Data Set 13 1.2.1.2 High-Throughput Screening Data with Imbalanced Data Distribution 14 1.2.1.3 Notoriously Difficult Endpoints – an hERG Toxicity dataset 15 1.2.1.4 Training Data Selection Criteria 16 1.2.2 Methods 17 1.2.2.1 Molecular Descriptors 17 1.2.2.1.1 Universal 4D-Fingerprints 17 1.2.2.1.2 MOE descriptors 21 1.2.2.2 The Construction of Binary Classification QSAR Models 22 1.2.2.3 Support Vector Machines 23 1.2.2.4 Model Evaluation 26 1.3 Results and Discussion 28 1.3.1 Binary Classification QSAR Models to a High-Quality Assay Data Set 28 1.3.1.1 Molecular Similarity Characterization of the Training and Test Sets 28 1.3.1.2 Selection of Descriptors and Continuous QSAR Models 30 1.3.1.3 Binary QSAR Predictions Derived From the Continuous QSAR Models 31 1.3.1.4 Determination of the Best QSAR Models 33 1.3.1.5 Statistical and Mechanistic Interpretation of the 4D-FPs and MOE Descriptors of the Best Model 39 1.3.1.6 Model Validation Using the PubChem Bioassay Test Set and Additional Literature Set 46 1.3.1.7 Model Comparisons 53 1.3.1.8 Discussion 55 1.3.2 A SVM Classification Model to a High-Throughput Screening Data with Imbalanced Data Distribution 62 1.3.2.1 SVM Model Building Using the Raw High-Throughput Screening Data 64 1.3.2.2 SVM Model Building by Adopting the Lipinski Rule-of-Five Filter 64 1.3.2.3 SVM Model Building by Adopting the logP Filter 66 1.3.2.4 SVM Model Building by Keeping all Active Compounds 69 1.3.2.5 Application of Two Sampling Methods for Treating ‘imbalance’ Datasets 70 1.3.2.6 Characterization of the Contributions of Molecular Descriptors to the Classification Models 71 1.3.2.7 Extraction of Features from Linear SVM Model for Descriptor Reduction 75 1.3.2.8 Interpretation of Descriptors and Exploration of the Best SVM Model 86 1.3.2.9 Model Comparisons 98 1.3.3 Recipes for Notoriously Difficult Endpoints – an hERG Toxicity Dataset 101 1.3.3.1 Model Building Using the Raw Difficult Endpoints 101 1.3.3.2 Model Building Using “F-score” Filter for Feature Selection 103 1.3.3.3 Model Building by Adopting the logP Filter and Reduced 4D-FPs 105 1.3.3.4 Model Comparisons 109 1.3.3.5 Interpretation of key descriptors 111 1.4 Conclusion 114 2 Template-based de novo Design for Type II Kinase Inhibitors 118 2.1 Introduction 118 2.2 Material and Methods 121 2.2.1 Data 122 2.2.2 Main Algorithm for Generating the New Structures 124 2.2.3 Molecular Dynamic Simulations 128 2.3 Results and Discussion 129 2.3.1 Sorafenib Reassembly 129 2.3.2 Nilotinib Reassembly 133 2.3.3 Optimization on the Series of Aminoisoquinoline Derivatives 136 2.4 Conclusions 138 3 Dynamic Programming Algorithms for Chemical Substituents-Core Combinatorial Problem 139 3.1 Introduction 139 3.1.1 Background 139 3.1.2 Chemical Substituents-Core Combinatorial Problem 140 3.1.3 NP-Completeness of Chemical Substituents-Core Combinatorial Problem 145 3.2 Methods 150 3.2.1 Dynamic Programming Algorithm for the Chemical Substituents-Core Combinatorial Problem 150 3.2.2 Time Complexity for the Dynamic Programming Algorithm 156 3.2.3 Iterative Dynamic Programming Algorithm for the Chemical Substituents-Core Combinatorial Problem 156 3.2.4 Time Complicity for the Iterative Dynamic Programming Algorithm 162 3.3 Experimental Results for Case Studies and Discussion 164 3.3.1 Results Verifications 164 3.3.2 Time Performance Comparison with Previous study 176 3.3.3 Benefits on Reinforced Results 178 3.3.4 Time Performance Comparison Between Classical Dynamic Programming and Iterative Dynamic Programming Algorithm 180 3.3.5 The Running Iterations in Iterative Dynamic Programming Algorithm 181 3.4 Concluding Remarks 183 Bibliography 184 Appendix 193 | |
dc.language.iso | en | |
dc.title | 新藥設計及化學結構組合最佳化與心毒性模擬 | zh_TW |
dc.title | A Chemical Substituents-Core Combinatorial Optimization and hERG Toxicity Prediction in Drug Design | en |
dc.type | Thesis | |
dc.date.schoolyear | 100-2 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 陳健輝,趙坤茂,歐陽明,陳俊良 | |
dc.subject.keyword | 人類鉀離子通道基因,二元定量構效關係模型,支援向量機,模版為基礎的,新藥設計方法,第二型激化酵素抑制劑,非完全多項式,動態規劃,天然物, | zh_TW |
dc.subject.keyword | hERG,Binary QSAR model,SVM,Templated–based,de novo design,Type II kinase inhibitors,NP-complete,Dynamic programming,Natural products, | en |
dc.relation.page | 194 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2012-08-09 | |
dc.contributor.author-college | 電機資訊學院 | zh_TW |
dc.contributor.author-dept | 資訊工程學研究所 | zh_TW |
顯示於系所單位: | 資訊工程學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-101-1.pdf 目前未授權公開取用 | 3.11 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。